Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulbMona Khan, Laura Van Gerven, Liuliu Pan et al.|Cell|2021Cited by 392
Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trialLore Vanderbeke, Nico Janssen, Dennis C. J. J. Bergmans et al.|Intensive Care Medicine|2021Cited by 98
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Bruno François et al.|Critical Care|2022Cited by 93
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Alain Lepape, Hasan S. Jafri et al.|The Lancet Infectious Diseases|2021Cited by 88
Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusionJan J. De Waele, Eric A. J. Hoste, I. Danneels et al.|International Journal of Antimicrobial Agents|2013Cited by 36